Patients   with  activated  B-like
   profiles  show  a  higher  rate  of  death  than  those with GC B-like
   profiles, suggesting that DLCBL is two different diseases, and require
   different programs of chemotherapy.

   The  use of microarrays has revolutionized the diagnosis and treatment
   of these diseases.